Background: The rutin loaded chitosan-alginate nanoparticles (RCANP) were prepared using an ion gelation method. The optimized RCANP4 formulation composed of rutin: alginate: chitosan with the ratio of 1.24:5:2. The particle size, zeta potential, and entrapment efficiency of RCANP4 formulation were found to be 168.4 ± 11.23 nm, -24.7 ± 1.5 mV, and 91.23 ± 1.1%, respectively. The in vitro drug release of RCANP4 formulation was found to be 88.89 ± 2.9% within 24 h. The Fourier transform infrared spectroscopy (FT-IR) of RCANP4 revealed all characteristic groups of rutin, confirming the successful loading of rutin into the nanoparticles. Methods: Due to rutin entrapment in the chitosan sodium alginate matrix, a broad curve was observed in the Differential Scanning Calorimetry (DSC) study of RCANP4. The RCANP4 was found to be uniform and spherical revealed from Scanning Electron Microscopy (SEM) and Transmission Electron Microscopy (TEM). RCANP4 showed 3.54 times more bioavailability than free rutin, resulting in more internalization of rutin in systemic circulation. The results of plasma glucose levels of diabetic rats administered with RCANP4 and rutin were evident that RCANP4 showed effective antidiabetic activity compared to rutin. Results: The results obtained for glucose uptake in HepG2 cells, the RCANP4 caused a significant (P < 0.05) increase in glucose uptake in contrast to rutin. In vitro cytotoxicity results explained that RCANP4 could significantly (P < 0.05) reduce the cells viability rate compared with rutin. It may be due to the internalization of RCANP4 formulations in systemic circulation. Conclusion: The results also showed that RCANP4 could significantly reduce cell viability over 24 h and 48 h compared to free rutin.
Brain tumors arise from an uncontrolled proliferation of neural tissue cells or supportive glial tissue cells within the brain. The diagnosis and therapy of brain tumor is an extremely challenging task. Moreover, absence of early stage symptoms and consequently delays in diagnosis and therapy worsen its severity. Though in the present days, chemotherapeutic approach is the most common therapeutic approach; still it is linked with several precincts. The blood-brain barrier (BBB) is the main hurdle in delivering most of the chemotherapeutic agents as well as imaging agent that leads to insufficient accumulation of therapeutic / imaging agents at tumor site, and prevents adequate destruction of malignant cells. Recently, lipid based nanoparticles are gaining much more interest and are preferred over polymeric nanoparticles owing to their biodegradability, non-toxicity, excellent tumortargeting ability and ease of surface modification. Certain receptors are over expressed in brain tumor cells which confer an opportunity to the researchers for delivering the chemotherapeutic as well as imaging agent particularly to the tumor cells through the surface modification approach of nanoparticles. Ligands like proteins/peptides, carbohydrates, aptamers, antibodies, and antibody fragments are generally conjugated to the surface of the nanoparticles that bind specifically to an over expressed target on the brain tumor cell surface. In the present review, we discuss the diagnostic and therapeutic application of various types of lipid based nanoparticles such as liposomes, niosomes, solid lipid nanoparticles, nanostructured lipid carrier, lipid nanocapsule, and lipid polymer hybrid nanocarriers along with their various surface modified forms for targeting brain tumor.
25 February 2022 in Turkish Journal of Pharmaceutical Sciences
The study aimed to explore the in vivo protective potential of rosuvastatin (ROSS), an oral antihyperlipidemic drug against doxorubicin (DOXO) induced cardio toxicity in rats. Cardiac toxicity was induced by DOXO injection (10 mg/kg, i.p.), once on the 20th day of the experiment. Except for the control rats, all were received DOXO and the study was continued for up to 21 days. The influence of ROSS on acute treatment was analyzed by quantification of cardiac marker enzymes such as creatine kinase-MB (CK-MB), lactate dehydrogenase (LDH) and liver marker enzymes like aspartate aminotransferase (AST), alanine aminotransferase (ALT) along with the measurement of in vivo antioxidants like superoxide dismutase and catalase. To observe histological changes of myocardial tissue hematoxylin and eosin staining were used. Acute administration of DOXO resulted in a marked rise of cardiac marker enzymes that confirms the myocardial damage compared to control animals whereas administration of ROSS (10 mg/kg, p.o.) resulted in the significant reduction of CK-MB, LDH levels (p<0.05) and AST, ALT levels to a remarkable extent. Moreover, ROSS administration significantly increased the activities of various in vivo antioxidant levels. From the results, the acute administration of ROSS showed significant cardioprotective property, which was evidenced by a significant reduction of cardiac and liver marker enzymes along with significant improvement of in vivo antioxidant activities. Furthermore the results were supported with histopathological observations. Hence, it can be concluded that cardioprotective potential of ROSS may be through attenuation of oxidative stress by modulating oxidative damage in rats.
28 August 2023 in Journal of Dispersion Science and Technology